Pharmaron Beijing (03759) appoints Li Chengzong as the company's authorized representative.
Kanglong Chemical (03759) announced that Mr. Lou Xiaoqiang, a company director, will resign as the company's authorized representative under Listing Rule 3.05 due to a work reallocation, effective August 20, 2026. From the same date, the board has approved the appointment of Mr. Li Chengzong, a company director, to succeed Mr. Lou Xiaoqiang as the company's authorized representative. After resigning as the authorized representative, Mr. Lou Xiaoqiang will continue to serve as the company's Chief Operating Officer, President, and Executive Director, with no other changes to his authority and responsibilities.
Pharmaron Beijing (03759) announced that Mr. Lou Xiaoqiang, a director of the company, will step down from his position as the companys authorized representative under Listing Rule 3.05 due to adjustments in work responsibilities, effective August 20, 2026. From the same date, the Board of Directors has approved the appointment of Mr. Li Chengzong, a director of the company, to replace Mr. Lou Xiaoqiang as the company's authorized representative. After stepping down as the authorized representative, Mr. Lou Xiaoqiang will continue to serve as the Chief Operating Officer, President, and Executive Director of the company, with no other changes to his authority and responsibilities.
Related Articles
LUYE PHARMA (02186) is set to launch II phase clinical trials in China for its mRNA vaccine LY01620, intended for the treatment of cervical precancerous lesions and HPV-related tumors.
CHINA POWER (02380) achieved strong growth in its hydropower segment in the first half of the year, with clean energy installed capacity accounting for over 80%.
3SBIO (01530) released its mid-term results, with a net profit attributable to shareholders of 1.147 billion yuan, a decrease of 15.58% year-on-year.
LUYE PHARMA (02186) is set to launch II phase clinical trials in China for its mRNA vaccine LY01620, intended for the treatment of cervical precancerous lesions and HPV-related tumors.
CHINA POWER (02380) achieved strong growth in its hydropower segment in the first half of the year, with clean energy installed capacity accounting for over 80%.
3SBIO (01530) released its mid-term results, with a net profit attributable to shareholders of 1.147 billion yuan, a decrease of 15.58% year-on-year.
RECOMMEND
